Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Recruiting

Phase 3

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Sponsor:

Neurocrine Biosciences

Code:

NCT05206513

Conditions

Dyskinesia

Cerebral Palsy

Eligibility Criteria

Sex: All

Age: 6 - 70

Healthy Volunteers: Not accepted

Interventions

Placebo

Valbenazine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Neurocrine Biosciences on 2025-05-25.